Brian Park, PharmD

Drug Information Specialist https://www.rheumatologyadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

General Rheumatology

CDC: COVID-19 Vaccine Breakthrough Infections Investigated

Brian Park, PharmD

June 3, 2021

The report included 10262 SARS-CoV-2 vaccine breakthrough infections in 46 US states and territories among 101 million fully vaccinated individuals as of April 30, 2021.

scientist, researcher using computer, data

General Rheumatology

FDA: Current Data Do Not Support Leronlimab for COVID-19

Brian Park, PharmD

June 1, 2021

Results showed both trials of leronlimab did not meet primary or secondary endpoints.

Spondyloarthritis

Apremilast to Be Reviewed for Mild to Moderate Plaque Psoriasis

Brian Park, PharmD

May 12, 2021

The sNDA is supported by data from the multicenter, double-blind, placebo-controlled phase 3 ADVANCE trial.

General Rheumatology

Trial Evaluating Dapagliflozin in Hospitalized Patients With COVID-19 Misses Endpoints

Brian Park, PharmD

May 7, 2021

The DARE-19 trial evaluated dapagliflozin in addition to standard of care in reducing disease progression, clinical complications and all-cause mortality in 1250 adults hospitalized with COVID-19.

General Rheumatology

Vaccination Reduces Risk for COVID-19-Associated Hospitalizations in Older Adults

Brian Park, PharmD

May 5, 2021

The analysis included adults 65 years of age and older with COVID-19-like illness admitted to 24 hospitals in 14 states during January 1, 2021 through March 26, 2021.

General Rheumatology

CDC, FDA: Use of Janssen COVID-19 Vaccine Should Resume

Brian Park, PharmD

April 30, 2021

As of April 23, 2021, a total of 15 cases of TTS have been reported to VAERS, including the original 6 reported cases.

General Rheumatology

FDA: Issues Identified at Proposed Manufacturing Facility for Janssen COVID-19 Vaccine

Brian Park, PharmD

April 27, 2021

The FDA recently completed an inspection of Emergent BioSolutions, a proposed manufacturing facility for the Janssen COVID-19 vaccine.

General Rheumatology

CDC, FDA Recommend Pausing Janssen COVID-19 Vaccine After Reports of Rare Blood Clot

Brian Park, PharmD

April 16, 2021

In all 6 cases, symptoms developed 6 to 13 days after vaccination.

General Rheumatology

CDC Updates Travel Guidance for Individuals Fully Vaccinated Against COVID-19

Brian Park, PharmD

April 16, 2021

Fully vaccinated individuals can travel within the US without having the need for COVID-19 testing or post-travel self-quarantine.

doctor holding vial of monoclonal antibodies, COVID-19

General Rheumatology

Monoclonal Antibody Combination Reduces Viral Load in Low-Risk COVID-19

Brian Park, PharmD

April 9, 2021

Preclinical data suggest that the combination of bamlanivimab and VIR-7831 may provide protection against current SARS-CoV-2 variants that have been resistant to bamlanivimab.

Next post in General Rheumatology